Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene therapy
Biotech
Ocugen update charts course for rivalry with Apellis, Astellas
Ocugen reported phase 2 data on its eye disease gene therapy, providing evidence that the candidate may outperform drugs from Apellis and Astellas.
Nick Paul Taylor
Jan 15, 2026 9:22am
Encoded deciphers pivotal path with phase 1/2 gene therapy data
Dec 5, 2025 12:45pm
FDA unveils new pathway to speed custom gene editing therapies
Nov 12, 2025 5:00pm
FDA puts Tenaya heart disease gene therapy trial on hold
Nov 10, 2025 5:16am
uniQure's gene therapy for Huntington's hits FDA roadblock
Nov 3, 2025 10:03am
Astellas turns down option to license Taysha gene therapy—again
Oct 17, 2025 10:50am
